May 2026 witnessed significant shifts in healthcare leadership across major organizations, alongside notable layoffs, signaling changes in strategic direction and operational priorities within the sector.
May 2026 witnessed significant shifts in healthcare leadership across major organizations, alongside notable layoffs, signaling changes in strategic direction and operational priorities within the sector.
READ MORE
Replimune Resubmits Its RP1 Melanoma Immunotherapy for FDA Approval Following Departure of Previous Decision Makers.
The Trump administration unveiled a comprehensive proposal to fundamentally change the regulations governing federal grants, stirring uncertainty and concern in the research community.
Pfizer expands its oncology portfolio through a substantial partnership agreement with Innovent Biologics, aiming to develop and commercialize a dozen novel antibody-based cancer therapies.
The Massachusetts Attorney General has filed a lawsuit against UnitedHealthcare, accusing the insurer of fraudulent practices by inflating the health risks of Medicaid members to increase profits.
AbbVie's antibody-drug conjugate Decnupaz has received FDA approval for treating blastic plasmacytoid dendritic cell neoplasm (BPDCN), an ultra-rare and aggressive blood cancer.
The transformational impact of AI in medical imaging may not lie solely in autonomous diagnosis but in creating tools that help patients better understand their radiology results.
Walmart and Teladoc Health have joined forces to enhance the availability of virtual care by integrating Teladoc's services into Walmart’s Better Care Services platform.
The FDA's recent relaxation of oversight on wellness devices has resulted in a marked increase in the availability of wearables claiming to monitor blood pressure, many of which lack proper validation.
Kailera Therapeutics is advancing a portfolio of weight loss treatments closely aligned with Eli Lilly’s established GLP-1 and GIP dual agonist medicines, signaling competitive strides in obesity therapeutics.
In today's employer-driven market, biopharma professionals face unique challenges when negotiating job offers. Experts weigh in on whether negotiation is advisable, common pitfalls, and strategic tips.
